Evaluating diagnostic accuracies of Panbio™ COVID-19 rapid antigen test and RT-PCR for the detection of SARS-CoV-2 in Addis Ababa, Ethiopia using Bayesian Latent-Class Models (BLCM) Abay Sisay<sup>1, 2, ¶,\*</sup>, Sonja Hartnack<sup>3, ¶</sup>, Abebaw Tiruneh<sup>1, 4</sup>, Yasin Desalegn<sup>4</sup>, Abraham Tesfaye<sup>1,5</sup>, Adey Feleke Desta<sup>2</sup> Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, <sup>2</sup>Department of Microbial, Cellular and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia <sup>3</sup>Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland <sup>4</sup>Addis Ababa Public Health Research and Emergency Management Laboratory, Addis Ababa Health Bureau, Addis Ababa, Ethiopia <sup>5</sup>Diagnostic Unit, Center for Innovative Drug Development and Therapeutic Trials for Africa, CDT- Africa, Addis Ababa, Ethiopia \*Corresponding author ¶ These authors contributed equally to this work

**Abstract** 

28

53

54

55

29 Background: Rapid diagnostics are vital for curving the transmission and control of COVID-19 pandemic. Although many commercially available antigen-based rapid diagnostic tests (Ag-30 RDTs) for the detection of SARS-CoV-2 are recommended by the WHO, their diagnostic 31 32 performance has not yet been assessed in Ethiopia. So far, the vast majority of studies assessing diagnostic accuracies of rapid antigen tests considered RT-PCR as a gold standard, 33 which inevitably leads to bias when RT-PCR is not 100% sensitive and specific. Thus, this study 34 aimed to evaluate the diagnostic performance of Panbio <sup>™</sup> COVID-19 rapid antigen test jointly 35 together with the RT-PCR for the detection of SARS-CoV-2. 36 37 Methods: A prospective cross-sectional study was done from July to September 2021 in Addis Ababa, Ethiopia, during the third wave of the pandemic involving two health centers and two 38 hospitals. Diagnostic sensitivity and specificity of Panbio™ rapid antigen test and RT-PCR were 39 obtained using Bayesian Latent-Class Models (BLCM). 40 **Results:** 438 COVID-19 presumptive clients were enrolled, 239 (54.6%) were females, of whom 41 196 (44.7%) had a positive RT-PCR and 158 (36.1%) were Ag-RDT positive. The Ag-RDT and RT-42 PCR had a sensitivity (95% CrI) of 99.6 (98.4-100), 89.3 (83.2-97.6) and specificity (95% CrI) of 43 93.4 (82.3 - 100), 99.1 (97.5- 100) respectively. Most of the study participants, 318 (72.6) 44 exhibited COVID-19 symptoms and the most reported was cough 191 (43.6). 45 **Conclusion:** The diagnostic performance of Panbio<sup>™</sup> COVID-19 Ag RDT is coherent with the 46 47 WHO established criteria of having a sensitivity ≥80% for Ag-RDTs. Superior performance of 48 the Panbio<sup>™</sup> RDT was documented in samples with the lowest cycle-threshold RT-PCR values 49 and clients with confirmed clinical symptoms. Thus, we recommend the use of the Panbio™ 50 RDT for both symptomatic and asymptomatic individuals in clinical settings for screening 51 purposes. 52

**Key words:** diagnostic sensitivity, diagnostic specificity, no gold standard, rapid diagnostic tests

### INTRODUCTION

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

The global public health and economic threats that resulted in countless disastrous effects due to COVID-19 is being revealed in numerous ways and it's not yet over. More than 6,223,645 deaths from over 504,834,324 documented cases have been reported as of April 18, 2022, since its detection in December 2019 and its being declared as public health emergency in March 2020 [1, 2,3]. In Africa, the current health systems and laboratory diagnostic capacities are at their questionable with respect to managing outbreaks as early as possible. Accordingly, realizing the 2030 SDG with lots of pitfalls in the diagnostic capacity and with so many people failing to get diagnosed. Irrefutably, rapid diagnostic tests are fundamental components of a successful outbreak containment strategy by prompt identification of cases that minimize response costs and save lives due to outbreak of the current COVID -19 [4, 5]. Ethiopia, being one of the countries with limited trained human and material resources is no exception, being the 6<sup>th</sup> in Africa with 468,895 COVID-19 cases. The country had experienced its fourth wave with an overwhelmingly rapid community transmission compared with the previous epidemic waves, having 35% of positivity rate and 56,706 new cases (Data of December 2021) [3, 6]. Despite this, the country has been tackling the pandemic through allocation of the limited resources for the transmission prevention and implementation of a uniform evidence-based preventive protocol at all levels of the health care system under central command, which is considered as a wise decision for optimal resource utilization [7, 8]. The current choice of established tests for the diagnosis of COVID-19 with a relatively better diagnostic performance using respiratory swab sample is RT-PCR, but its affordability and infrastructure demand for most laboratories in the low-income countries are atypical. Alternative testing modalities have become convenient approaches to reach more clients and a step forward to empower individuals by bringing healthcare services closer to them. In view

of this, rapid antigen tests have been in place as an option with their comparable diagnostic

performance [9-11].

The impact of rapid diagnostic testing (RDT) has been significant because results can be

delivered in short turnaround time of COVID-19 testing. RDT has become a game-changer for

triaging patients and crucial medical decisions [7,12]. Compared to RDT, the procedure of RT-

PCR is sophisticated, may lead to specimen contamination and technical personnel are prone

to acquiring the virus while demand samples from the presumptive cases [4]. On the other

hand, several RDTs have been and are currently being developed and commercialized [4, 7,13].

Despite the ease of application and low cost, RDTs are still in need of attention on their quality

diagnostic performance for the containment of the virus [14,15].

Since May 2021, Ethiopia has started using Panbio<sup>™</sup> COVID-19 rapid antigen test for the diagnosis of COVID-19 in line with RT-PCR [16,17]. Yet, there has been no documented evidence on its diagnostic performance. Indeed, the pandemic urges to have an evidence-based information on its diagnostic accuracy as critically and timely imperative for the program and has its impact in the containment strategy and for continuous quality improvements on its implementation as part of the pandemic control [11,18,19, 20]. Moreover, a lot of studies are available elsewhere that evaluated Panbio<sup>™</sup> COVID-19 Ag-RDTs against RT-PCR as the gold standard [21-24], which inevitably leads to bias. Yet, no study has been conducted using BLCM. Thus, this study aimed to assess the diagnostic performance of Panbio<sup>™</sup> rapid antigen test for the detection of SARS-CoV-2 in Addis Ababa, Ethiopia using BLCM to bridge the lack of performance accuracy in clinical setting.

## Materials and methods

## Study design, period and settings

A health facility-based prospective cross-sectional diagnostic test evaluation study was conducted from July to September 2021, during on the third wave of the epidemic, among COVID-19 presumptive clients in public health facilities of Addis Ababa, Ethiopia. The study

site, Addis Ababa is described in Sisay A. and colleagues,2022 [17]. As part of the current pandemic response, the Addis Ababa Health bureau selected 20 health centers: which is 2 health centers from the ten sub cities, it is based on the previous sub city classification and 6 hospitals for the pilot and start up implementation of this rapid antigen test, Panbio<sup>TM</sup> (Abbott) rapid antigen test kit for the detection of SARS-CoV-2 using nasopharyngeal swabs against. From these sites, we have selected two government health centers (Kazanches, Kotebe) and two hospitals (Zewuditu Memorial Hospital, Ras Desta Damitew Memorial Hospital). These two public hospitals are amongst the largest and the referral health care system promotes and provides preventive, curative and rehabilitative outpatient care including basic laboratory services [25,26].

### Sampling method

The study population were all presumptive COVID-19 clients among public health facilities of Addis Ababa who were willing to take part in the study and were available during data collection period. We employed a convenience sampling technique until it reached a maximum saturation point (n=438). Stratification of the samples in the four selected sites was done based on the health facilities' previous three months of SARS-CoV-2 testing performance and availability of resources (see annex 1). The sampling also considered contingency for non-response, invalid and contamination for assuring the best representativeness of the specimens.

## Flow of study Participants

In this study, eligible participants from community surveillance, contacts of confirmed cases, and suspects who fulfill the WHO criteria and Ethiopian guideline for COVID-19 cases were screened by trained professionals as quick triage system [27]. Of these, a total of 438 nasopharyngeal swabs was collected by trained health professionals.

We excluded the critically ill cases, confirmed COVID-19 positive patients and with age  $\leq$  18 years old. Regarding test kit selection, Panbio<sup>TM</sup> COVID-19 Ag RDT was used for our study

mainly because Panbio™ RDT was the only locally available test kit listed by WHO and authorized by the Ethiopian regulatory body for laboratory utilization [27, 28].

### Methods of Sample collection and data collection instruments

We collected the nasopharyngeal respiratory specimens twice from each study participant upon consent using viral transport medium: one for rapid antigen and the other for RT-PCR. The rapid Ag tests were analyzed immediately according to the manufacturers' instruction by the primary investigators and results were obtained by the visual interpretation of each testers. The other collected specimen was placed in 3 mL of Viral Transport Medium (VTM) and packed by triple packing system for maintaining the safety measures and shipped immediately to Addis Ababa Public health research and emergency management center laboratory (AAPHEML) for RT-PCR testing. The clinical specimens were collected with strict bio safety measure and lab procedure of Panbio rapid Ag. The quantitative data were collected using a structured data collection tool, prepared was developed in English language after reviewing relevant literature. It included the socio-demographic characteristics and client's clinical information used for the analysis of the finding of the study [28,29].

## **Laboratory Testing Procedures**

### RT- PCR SARS-CoV-2 testing

2 mL VTM (China, Miraclean Technology Co., Ltd., www.mantacc.com) nasopharyngeal specimens were collected and all the nasopharyngeal samples were extracted in BIOER auto method extraction machine with MgaBio plus virus RNA purification kit II and analyzed by using Sansure Biotech (MA-6000) SARS-CoV-2 RT-PCR assay on the BGI Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 in a real-time reverse transcription polymerase chain reaction (RT-PCR) test. The assay developed for detecting specific single target gene, which is found on the ORF1ab region of SARS-CoV-2 genome. Further, human housekeeping gene  $\beta$ -Actin is the target gene for the internal control. The master mixing was done by mixing 20 $\mu$ l master mix reagent and 10 $\mu$ l of the extracted sample RNA to the well pre filled with PCR-Mix in the following order: no template (negative) control, patient specimen(s), and positive

control. The reference test with a cycle threshold (Ct) < 38 as the criteria for a positive result if Ct value of internal reference not higher than 32 at VIC/HEX and specimen is negative ORF1ab/FAM as 0 or no data available while Ct value at VIC/HEX not higher than 32 [30].

### Ag-RDT SARS-CoV-2 testing

The collected nasopharyngeal swab was processed on site using the Panbio<sup>™</sup> Ag-RDT (Abbott Diagnostic GmbH, Germany). The samples from the swab are mixed with approximately 300 µl of buffer, and then add 5 drops are dispensed into the device. The results were interpreted in 15 -20 minutes following in the manufacturer's instruction but the results do not read after 20 minutes. It detects the presence of the nucleo capsid (N) proteins of the virus on a membrane based using an immune chromatography assay. For a positive result with the Panbio (Abbot) test, a test line must form in the result window (T) and a control (C) line is visible to indicate a test result is valid. In the Negative result is the presence of only the control line(C) and no test line (T) within the result window seen. Invalid result was not occurred in our study if the test line nor the control line was not visible in the result window prior to the specimen dispensed on the device [29]. The test was performed as per Panbio<sup>™</sup> COVID-19 Ag Rapid Test Device (NASAL), in vitro diagnostic rapid test for qualitative detection of SARS-CoV-2 antigen (Ag) in a strictly safety percolations [28].

## **Data quality Assurance**

Data compilers and laboratory workers get its appropriate orientation on how to perform and how to assure valid data using the tool and additional written guide have been provided to them on interpreting each of the study variables. The principal investigators have closely supervised the data collection process so as to ensure the completeness and consistency of the data collection. The laboratory testing was done as per its approved documented standard operating procedures and manufacturer recommendations. In all extraction procedures, as part of assuring the quality management system, we always incorporate a positive and negative quality controls. In addition, data were double entered to prevent error during data entry via cross-checking and also finally checked and verified prior to analysis.

### **Data analysis and Interpretation**

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Descriptive data of the research was entered and analyzed using SPSS statistical software version 23. The rapid antigen test results obtained by visual interpretation were interpreted as positive and negative based on the inbuilt internal control. The RT-PCR laboratory results were interpreted as positive and negative based on the cut-off Ct values of the manufacturer recommendation. All laboratory test results were considered valid if and only if the internal quality control were passed. The binomial 95 % confidence intervals which were obtained following Jeffreys approach in the R package DescTools were used (R version 4.1.3)[and Cohen's kappa value to assess the agreement beyond chance were obtained with the R package psych [31,34,35]. A value of 1 implies almost perfect agreement and values less than 1 implies less than perfect agreement, with a range of values between 0 and 1 [30,31].

## Bayesian latent class model (BLCM)

With the aim to obtain diagnostic tests accuracies in the absence of a perfect gold standard, Bayesian latent class models (BLCM) were fit to the data following the approach from Hui and Walter for two tests and four populations with MCMC (Markov chain Monte Carlo) simulation to construct posteriors in JAGS version 4.3.0 [32] using the runjags package [33]. The frequencies of the four combinations of dichotomized Panbio and RT-PCR results (++; +-; -+;--) in the four populations, respectively, were modeled with a multinomial distribution. To allow for potential conditional dependencies, pair wise covariance between sensitivities and specificities of all RT-PCRs were included in separate models. Model selection, i.e., in- or exclusion of conditional dependencies was based on the 95% credibility intervals (including o or not) and on Bayesian p-values. The model code (S1 File) was obtained with the function "auto huiwalter" of the runjags package [34], with three chains of 50 000 iterations each, a burn-in of 5000 iterations, and a thinning of 10 iterations. Minimally informative priors (beta (1,1)) were used for the sensitivities of both tests, the specificity of Panbio and the four prevalences. The shape parameters for the specificity of the RT-PCR were obtained with beta buster assuming "to be 95% sure that the specificity is greater than 90% with a mode at 99%" as prior information. Convergence was assessed by visual inspection of the trace plots and

the potential scale reduction factor (Gelman Rubin statistic) being below 1.1. A sensitivity analysis was performed by using different combinations of minimally (dbeta(1,1)) or weakly informative priors (dbeta(2,1)) **Ethical consideration** Ethical approval was obtained from IRB of department of medical laboratory Sciences, College of Health Sciences, Addis Ababa University (reference-MLS/174/21)), IRB office of Health bureau, AAPHREML (Reference-AAHB/4039/227) and also from Addis Ababa University, College of natural and computational science IRB (IRB-CNCSDO/604/13/2021). Additionally, AAPHREML wrote support letter to the study health facilities. During data collection process the data collectors informed each study health facility and study participants about the purpose and anticipate benefits of the research and on their full right to refuse, withdraw or completely reject part or all of their part in the study. Written informed consent on the use of data with full anonymity was obtained from the voluntary participants. This work has been done and performed as per Helsinki declaration.

Results

Socio-demographic characteristics of the study variables of participants A total of 438 presumptive clients were identified and enrolled in this study and the majority of them, 239 (54.6%) were females and the age of the participants were ranging from 18 to 84 years and the mean age was  $36.38 \pm 14.3$  years. Three fourth of the study participants (n=318) had symptoms of COVID-19 and the most reported clinical symptoms were cough (n=191), followed by headache (n=39). For more than half (n=258) of the participants, the reason for getting tested was due to observing the classic symptoms. The detail demographic data were depicted in table 1.

# Table 1. Demographic characteristics of study participants and cross-classified results of RT-PCR and Panbio, Addis Ababa, Ethiopia, 2021 (n=438)

261

		· ,	RT-PCR positive test results	Panbio positive test results
Variable		N (%)[95% CI]	N (%)	N (%)
			[95% CI]	[95% CI]
Gender	Male	199 (45.3)[40.8;50.1]	92 (46.2)[39.4;53.2]	78 (39.2)[32.6;46.1]
	Female	239 (54.6)[49.9;59.2]	104 (43.5)[37.2;49.8]	80 (33.5)[27.7;39.6]
Occupation	Health worker	17 (3.9)[0.0;8.9]	11 (64.7)[41.1;83.7]	10 (58.8)[35.6;79.3]
	Government	97 (22.1)[17.3;27.2]	48 (49.59[39.7;59.3]	41 (42.3)[32.8;52.2]
	Employee			
	Self employed	63 (14.4)[9.6;19.4]	29 (46.0) [34.1;58.3]	28 (44.4)[32.6;56.7]
	Private employee	118 (26.9)[22.1;32-0]	48 (40.7) [32.1;49.7]	32 (27.1)[19.7;35.6]
	NGO employee	9 (2.0) [0.0;7.1]	4 (44.4)[17.3;74.6]	4 (44.4)[17.3;74.6]
	No response /Others	134 (30.6)[25.8;35.6]	56 (41.8)[33.7;50.2]	43 (32.1)[24.6;40.3]
COVID-19	Yes	318 (72.6)[68.5;76.9]	164 (51.6)[46.1;57.0]	139
symptoms	103			(43.7)[38.3;49.2]
	No	118 (26.9)[22.8;31.2]	32 (27.1)[19.7;35.6]	19 (16.1)[10.3;23.5]
	Don't know	2 (0.4)[0;4.7]	o (o)[o;6.7]	o (o)[o;6.7]
clinical	Cough	191 (43.6)[38.8;48.5]	107 (56.0)[48.9;62.9]	91 (47.6)[40.6;54.7]
symptoms	Fever	33 (7.5)[2.7;12.4]	14 (42.2)[26.8;59.3]	11 (33.3)[19.2;50.3]
	Shortness of breath	13 (3.0)[0;7.8]	6 (46.1)[22.1;71.7]	6 (46.1)[22.1;71.7]
	Sore throat	21 (4.8)[0;9.6]	7 (33.3)[16.3;54.6]	6 (28.6)[12.9;49.7]
	Headache	39 (8.9)[4.1;13.8]	15 (38.5)[24.5;54.1]	9 (23.1)[12.1;37.9]
	Easy fatigue	6 (1.4)[0;6.2]	3 (50)[16.7;83.3]	3 (50)[16.7;83.3]
	Loss of smell and /or	4 (0.9)[0;5.8]	2 (50)[12.3;87.7]	2 (50)[12.3;87.7]
	taste			
	Joint &/or muscle pain	13 (3.0)[0;7.8]	11 (84.6)[59.1;96.6]	11 (84.6)[59.1;96.6]
	1 to 8(All symptoms)	2 (0.4)[0,5.3]	2 (100)[33.3;100]	2 (100)[33.3;100]
	No response	116 (26.5)[21.7;31.3]	29 (25)[17.8;33.4]	17 (14.6)[9.1;21.9]
Have	yes	57 (13.0)[10.1;16.4]	26 (45.6)[33.2;58.5]	22 (38.6)[26.8;51.5]
comorbidity	No/no answer	381 (87.0)[83.6;89.9]	170 (44.6)[39.7;49.6]	136
_		. ( )	( ) [ 1 10 ]	(35.7)[31.0;40.6]
Type of	DM	26 (5.9)[3.2;9.1]	13 (50)[31.6;68.4]	12 (46.1)[28.2;64.9]
comorbidity	Hypertensive	25 (5.7)[3.0;8.9]	14 (56)[36.8;73.9]	10 (40)[22.7;59.4]
	HIV/AIDS	2 (0.4)[0;3.6]	1 (50)[6.1;93.9]	1 (50)[6.1; 93.9]
	Chronic respiratory D/s	3 (0.7)[0;3.8]	1 (33.3)[3.9;82.3]	1 (33.3)[3.8;82.3]
	Chronic Cardiac D/S	2 (0.4)[0;3.6]	0 (0)[0;66.7]	o (o)[o;66.7]
	Malignancy	2 (04)[0;3.6]	1 (50)[6.1;93.9]	1 (50)[6.1;93.9]
	Other and have no	378 (86.3)[83.6;89.5]	166 (44.1)[39.2;49.2]	133 (35.2)[30.5;40.1]
	comorbidity			

Ta	hl	6	1	c	۱n	+′
ıα	v			$\sim$	/I I	ι.

Contact	Yes	170 (38.8)[34.2;43.6]	50 (29.4)[22.9;36.6]	34 (20)[14.5;26.5]
with	No	266 (60.7)[56.2;65.6]	146 (54.9)[48.9;60.8]	124
confirmed				(46.6)[40.7;52.6]
case	Others	2 (0.4)[0;5.3]	o (o)[o;66.7]	o (o)[o;66.7]
Assumed	Home	83 (18.9)[14.1;23.9]	30 (36.1)[26.4;46.8]	20 (24.1)[15.9;34.1]
place of	Workplace	114 (26.0)[21.2;31.0]	40 (35.1)[26.8;44.1]	31 (27.2)[19.7;35.8]
exposure	Health facility	1 (0.2)[0;5.2]	o (o)[o;85.3]	o (o)[o;85.3]
	Others	3 (0.7)[0;5.6]	o (o)[o;53.5]	0 (0)[0;53.5]
	Not recognized	237 (54.1)[49.3;59.0]	126 (53.2)[46.8;59.4]	107 (45.1)[38.9;51.5]
Previously	Yes	60 (13.7)[10.7;17.1]	23 (38.3)[26.8;50.9]	14 (23.3)[14.0;35.1]
tested	No	378 (86.3)[82.8;89.3]	173 (45.8)[40.8;50.8]	144 (38.1)[33.3;43.1]
positive				
Covid-19	Yes	49 (11.2)[8.5;14.4]	17 (34.7)[22.5;48.6]	11 (22.4)[12.5;35.5]
vaccination	No	389 (88.8)[85.6;91.5]	179 (46.0)[41.1;51.0]	147 (37.8)[33.1;42.7]
Wear face	Yes	426 (97.3)[96.1;98.7]	187 (43.9)[39.2;48.6]	151 (35.4)[31.0;40.1]
mask	No	6 (1.4)[0.2;2.9]	4 (66.7)[28.6;92.3]	4 (66.7)[28.6;92.3]
regularly	No response	6 (1.4)[0.2;2.9]	5 (83.3)[44.2;98.1]	3 (50)[16.7;83.3]
Reason for	Suspect	258 (58.9)[54.3;63.8]	140 (54.3)[48.2;60.3]	120
testing				(46.5)[40.5;52.6]
	Contact of confirmed	177 (40.4)[35.8;45.3]	56 (31.6)[25.1;38.7]	38 (21.5)[15.9;27.9]
	case			
	Community	3 (0.7)[0;5.6]	o (o)[o:53.5]	0 (0)[0:53.5]
	surveillance			
Health	Zewdito Memorial	46 (10.5)[5,7;15.3]	23 (50)[35.9;64.1]	20 (43.5)[29.9;57.8]
facility	hospital(HF1)			
	Ras Desta Damtew	230 (52.5)[47.7;57.3]	86 (37.4)[31.3;43.8]	63 (27.4)[21.9;33.4]
	Memorial Hospital(HF2)		( · ( · )[ · · · · (- · ]	( )[0 -1
	Kazenchis Health Center(HF3)	116 (26.5)[21.7;31.3]	62 (53.4)[44.4;62.3]	57 (49.1)[40.1;58.2]
	Kotebe Health	46 (10.5)[5.7;15.3]	25 (54.3)[40.0;68.1]	18 (39.1)[26.0;53.4]
	Center(HF4)	4º(¹º٠ɔ/[ɔ٠/,¹ɔ٠ɔ]	45 (54 <b>.</b> 5)[40 <b>.</b> 0,00.1]	10 (39.1)[20.0,33.4]
	3.( 1)			

## Test performance accuracy based on days since Clinical symptom onset

The performance accuracy of the RDT were high as of the lowest number of ct values as depicted in table 2. As the ct values of the test Sensitivity Performance of the Rapid Antigen Test Kits with the Date of Clinical Onset of Symptoms of the Clients, and ct values 2022, Addis Ababa, Ethiopia

#### Table 2- Test performance along date of clinical onset and its CT values, 2021, Addis Ababa, Ethiopia.

Date of clinical onset	RT PCR te	est result	-	RT PCR p	ositive test	result aloi	ng with ct.	Panbio result	Ag RDT	-
Cillical Offset	Positive	Negative	Total	Ct ≤25	Ct>25 to ≤30	>30 to Ct ≤35	>35 to Ct <38	Positive	Negativ e	Total
o-3days	63	75	138	50	9	1	3	56	82	138
4-7days	100	55	155	66	27	4	3	82	73	155
8-10 days	16	9	25	8	6	2	0	11	14	25
11-15 days	6	6	12	1	3	0	2	3	9	12
>15 days	2	30	32	0	1	0	1	1	31	32
No response	9	67	76	2	3	2	2	5	71	76
Total	196	242	438	127 *** 0	49 ver all Kap	9 oa value 81	11 % (95% CI:	158 75.82% to	280 87.45%)	438

## Diagnostic Performance of Panibo Ag test and RT-PCR using BLCM

We have performed BLCMs to assess the diagnostic performance of the Panbio<sup>™</sup> antigen test and RT-PCR in the absence of a gold standard using 4 population with 2 tests, with symptoms and without symptoms using BLCM. Accordingly, the Ag-RDT and RT-PCR had a sensitivity (95% CrI) of 99.6 % (98.4%-100 %), 89.3 % (83.2%-97.6%) and specificity (95% CrI) of 93.4% (82.3% -100 %), 99.1 % (97.5%-100%) respectively, table 3a.

Table 3 a- Performance of test kits using all model of BLCM, Addis Ababa, Ethiopia, 2021

	Model with all patients	Model: Patients	Model:Patients	
		with symptoms	without symptoms	
Variable	Median [95% Crl]	Median [95% CrI]	Median [95% Crl]	
Se_Panbio	99.6[98.4;100]	99.3[97.4;100]	99.2[96.6;100]	
Se_PCR	89.3[83.2;97.6]	91.4[83.8;100]	89.4[81.3;98.0]	
Sp_Panbio	93.4[82.3;100]	91.6[82.7;100]	83.6[58.6;100]	
Sp_PCR	99.1[97.5;100]	99.0[97.2;100]	98.0[93.1;100]	
Prev Hf1	54.0[39.3;68.4]	50.0[33.5;66.2]	64.4[36.3;89.1]	
Prev Hf2	70.0[62.1;77.1]	58.9[49.6;68.0]	90.5[80.7;97.4]	
Prev Hf3	49.1[39.4;58.5]	46.0[35.5;56.4]	57.8[37.7;76.5]	
Prev Hf4	55.2[38.7;71.2]	43.3[25.3;62.3]	76.8[51.7;95.6]	

The performance of Ag-RDT was also examined using different parameters or conditional dependency, as depicted in table 3b and S1-S6 (supplementary files, S1-S6).

Table 3 b: Performance of test kits on conditional dependency using BLCM, Addis Ababa, Ethiopia, 2021

	Model covariance	Model covariance
sensitivities		specificities
	Median [95% Crl]	Median [95% CrI]
Se_Panbio	91.6[71.8;100]	99.5[98.3;100]
Se_PCR	81.7[61.2;95.2]	89.0[82.7;97.4]
Sp_Panbio	92.9[80.3;100]	91.9[80.5;100]
Sp_PCR	98.9[96.4;100]	98.1[92.1;100]
Prev HF1	60.7[40.4;86.5]	53.1[37.9;68.0]
Prev HF2	77.0[65.9;100]	69.6[61.4;76.8]
Prev HF3	54.8[40.7;75.7]	48.3[37.8;58.1]
PrevHF4	61.9[40.1;88.1]	54.7[37.0;70.6]
Cov_se <sup>1</sup>	0.064[-0.0005;0.1757]	-
Cov_sp <sup>2</sup>	-	0.009[-0.0014;0.0066]

<sup>1:</sup> Bayesian p-value for covariance between sensitivity of Panbio and PCR 0.986

### **Discussion**

Accordingly, rapid Ag-based diagnostic tests that could pinpoint patients at early disease were commonly recommended. In this regard, the current status of our country's laboratory diagnosis system for COVID-19 is centralized with limited number of facilities resulted in longer turnaround of results, which goes against the escalation of the virus in a country having more than 100 million population and not more than 4,000 diagnostic medical laboratories [7, 16].

The diagnostic sensitivity and specificity of Panbio was comparable with reports by Nsoga *et. al.* with sensitivity and specificity ranges of 71.4%-91.7% and 94.9%-100%, respectively, while using RT-PCR as a gold standard. These study results also considered Ct values of <30 that yielded test sensitivities from 87.7% to 97.8% [36-38].

<sup>2:</sup> Bayesian p-value for covariance between specificity of Panbio and PCR 0.969

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

In terms of predictive values: when we use RT-PCR as gold standard, our finding had comparable PPV and incomparable NPV when compared and contrasted with a study by Bulilete et al., with the overall sensitivity of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the positive predictive value of 98.0% (95% CI: 93.0%, 99.7%) and a negative predictive value of 96.8% (95% CI: 95.7%, 97.7%) [39]. This indicates a clear difference in the specificity of the test performance among the negative cases, which may be due to the difference in study participant recruitments, which is we used more the asymptomatic and having clients with chief compliant of COVID-19 while presenting in the health facilities [39]. Our study finding illustrate more inline finding with the WHO stated criteria for the emergency use of clinical setting of such products as appropriate criteria, such as WHO's priority target product profiles for COVID-19 diagnostics of acceptable' sensitivity ≥ 80% and specificity ≥ 97%), can be considered as a replacement for laboratory-based RT-PCR when immediate decisions about patient care. This is truer in symptomatic clients and we are not sure that this performance be in asymptomatic cases. Indeed, Panbio™ COVID-19 Ag-RDTs has a similar sensitivity performance in both symptomatic and asymptomatic, but its specificity is lower among clients without symptoms. Whereas RT- PCR is slightly lower in clients among without symptoms [40, 41]. As a general principle RDTs can be used outside laboratories, at/ or near the point of care. They are easy to use, provide rapid results and do not require any expensive equipment. Ag-RDTs can be considered as alternatives to expand NAAT here (NAAT) for direct detection of SARS-CoV-2 virus for diagnosis of early COVID-19 and also its critical tool to scale-up testing and diagnostic in the fight against COVID-19 for the control of the pandemic. Nevertheless, we highly underline that these tests should be performed under strict follow-up of trained professional starting from the very beginning of pre analytical to post analytical of result dissemination [42]. A similar study conducted in Germany, Switzerland and Japan in comparing this RDT diagnostic performance and using RT-PCR as a gold standard method of the classical method model showed more comparable finding among symptomatic study participants and its

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

superior performance have been observed in case of samples having the lowest ct values and high amount of viral concentration. We understand that, there might be a direct relationship with the ct values and viral load of the study samples. However, because of resource limitation, we did not monitor the viral concentration of the clients and readers should consider it while inferring our finding with these studies [12, 15, 43, 44]. Our finding revealed the Panbio<sup>TM</sup> rapid antigen test have highest level of agreement of the inter-test agreement beyond chance of the established assays (RT-PCR) with an average Cohen's kappa value of 81% (95% CI: 75.82% to 87.45%) among our study subjects of 438 COVID-19 suspected individuals, which was consistent with similar studies [36, 37] and lower finding compared with Torres et. al., where the defined study population was different form the present study [45]. The diagnostic performance Panbio™ Covid-19 Ag rapid test highly correlate with Ct values and day of clinical onset. We found a superior performance in lowest ct values, which is most probably during at this condition the viral concentration become high and as the clinical onset of the day increase its performance among asymptomatic cases [37, 41]. Most of the false negative Ag-RDT results were among the population with contacts of SARS-CoV-2 confirmed patient within a week range of contact of confirmed case and they have reported no clinical symptoms and chief complaints when arriving at the testing health facilities. Their age ranged from 18 to 68 years old and most of them were female. Also there was a single false positive report from the total non-diseased of 242. The low frequency of false positive report of the AG-RDTwas in line with a study done by Bulilete and colleagues in Spain and Akingba and colleagues, in south Africa, while we consider RT-PCR as gold standard [38,39]. This study proved the presence of a clear difference in the performance of the test kits when taking RT-PCR as a perfect gold standard, instead of using BLCM assuming no gold standard.

# **Conclusion and recommendations**

The introduction of rapid antigen laboratory diagnostic methods in routine laboratory for identification of SARS-COV-2 for a possibility of expanding to the general service, especially near to the patients which could help medical practitioners for isolating the patients and intervention of infections that can help to combat the devastating transmission. Based on our study findings, the diagnostic performance of the Panbio<sup>TM</sup> Covid-19 RDT were 99.6 % sensitivity and 93.4 % specificity among presumptive cases of Addis Ababa, by which it qualify the WHO established criteria required to have for Ag-RDTs (sensitivity  $\geq$ 80% and specificity  $\geq$ 97%). Thus, it's highly recommended to use it in areas of symptomatic individuals. This can minimize reoccurrence and further spread of the pandemic and gripped the spread of the virus by testing all the presumptive. We highly recommended further large-scale study coupled with genomic approaches considering the presence of performance variation as the variant of concern continues to emerge.

### **Supporting information**

S1 – S6 are supplementary material used for this BLCM analysis, Addis Ababa, Ethiopia, 2022.

## **Authors' contributions**

- **Conceptualization:** Abay Sisay, Adey Feleke Desta
- Data curation: Abay Sisay, Abebaw Tiruneh, Yasin Desalegn, Abraham Tesfaye, Adey Feleke
- 370 Desta

- Formal analysis: Abay Sisay, Sonja Hartnack,
- **Investigation:** Abay Sisay, Sonja Hartnack ,Abebaw Tiruneh, Yasin Desalegn, Abraham
- 373 Tesfaye, Adey Feleke Desta
- **Methodology:** Abay Sisay, Sonja Hartnack ,Abebaw Tiruneh, Abraham Tesfaye, Adey Feleke
- 375 Desta
- **Project administration:** Abay Sisay,
- **Resources:** Abay Sisay,

**Software:** Abay Sisay, Sonja Hartnack, Adey Feleke Desta 378 Supervision: Abay Sisay, Sonja Hartnack ,Abebaw Tiruneh, Abraham Tesfaye, Adey Feleke 379 Desta 380 Validation: Abay Sisay, Sonja Hartnack, Abebaw Tiruneh, Abraham Tesfaye, Adey Feleke 381 Desta 382 Visualization: Abay Sisay, Sonja Hartnack, Adey Feleke Desta 383 Writing original draft: Abay Sisay, Sonja Hartnack 384 Writing review & editing: Abay Sisay, Sonja Hartnack, Abebaw Tiruneh, Yasin Desalegn, 385 Abraham Tesfaye, Adey Feleke Desta 386 **Conflicts of interest** 387 We, the authors declare that they have no known competing financial interests or personal 388 389 relationships that could have appeared to influence the work reported in this paper **Data Availability Statement** 390 All data set used in this study are included in this manuscript. 391 **Funding** 392 This work was financed by Addis Ababa University through adaptive research and problem 393 solving project, with project title, Evaluation and Validation of the Diagnostic Performance of 394 SARS-CoV-2 rapid test for the detection of Novel Corona Virus, Ref #-PR/5.15/590/12/20 and no 395 external funding was received. The funders anywhere not involved in study design, data 396 collection and analysis, decision to publish, or preparation of the manuscript. The contents 397 are purely the responsibilities of the authors and did not represent and reflect the view of the 398

funder.

## **Acknowledgments**

- We are very grateful and acknowledge the Addis Ababa University and Addis Ababa Health
- bureau, the Zewditu Memorial Hospital, the Ras Desta Damtew Memorial Hospital, the
- Kotebe Health Center and the Kazanches Health Center for granting their institutional ethical
- approval and their strong support and assistance in accessing diverse resources used in the
- 405 study.

407

408

409 410

411

400

We also acknowledge all the data collector and study participants.

### References

- 1. World Health Organization Best Practices for the Naming of New Human Infectious
  Diseases.https://apps.who.int/iris/bitstream/handle/10665/163636/WHO\_HSE\_FOS\_15.
- 414 <u>1\_eng.pdf</u>. Access date 12 March 2022.
- 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
- 417 3. University JH. Johns Hopkins University, J.H., worldometers COVID 19 Daily update. 418 worldometers. Available from: https://coronavirus.jhu.edu/. Accessed March 12, 2022.
- 4. Konrad R, Eberle U, Dangel A, et al. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Euro Surveill. 2020;25(9):2000173. doi:10.2807/1560-7917.ES.2020.25.9.2000173.
- 5. UN. Transforming our world: the 2030 Agenda for Sustainable
  Development.pdfhttps://sustainabledevelopment.un.org/post2015/transformingourw
  orld/publication.Aceess date March 20, 2022.
- 6. Ethiopian Public health Institutes. COVID-19 daily report.

  https://twitter.com/ephiethiopia. Aceess date March 20, 2022

- 7. Sisay A, Tesfaye A, Desale A, et al. Diagnostic Performance of SARS-CoV-2 IgM/IgG Rapid Test Kits for the Detection of the Novel Coronavirus in Ethiopia. *J Multidiscip*
- 429 Healthc. 2021; 14:171-180. Published 2021 Jan 27. doi:10.2147/JMDH.S290711
- 430 8. Abbot global Point of Care. PANBIO™ COVID-19 ANTIGEN SELF-TEST.
- 431 <a href="https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-ag-">https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-ag-</a>
- 432 <u>antigen-test.html</u>. Accessed date March 12, 2022.
- 9. Munne K, Bhanothu V, Bhor V, Patel V, Mahale SD, Pande S. Detection of SARS-CoV-2
- infection by RT-PCR test: factors influencing interpretation of results. Virus disease.
- 435 2021;32(2):187-189. doi:10.1007/s13337-021-00692-5
- 436 10. Sharma K, Aggarwala P, Gandhi D, Mathias A, Singh P, Sharma S, et al. (2021)
- 437 Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using
- 438 rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice.
- 439 PLoS ONE 16(4): e0249408. https://doi.org/10.1371/journal.pone.0249408
- 11. Goudouris ES. Laboratory diagnosis of COVID-19. J Pediatr (Rio J). 2021;97(1):7-12.
- doi:10.1016/j.jped.2020.08.001.
- 12. Eshghifar Nahal, BusheriAli, Shrestha Rojeet, Begaj Safedin, Evaluation of Analytical
- Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus.
- International Journal of General Medicine 2021:14 435–440
- 13. Won J, Lee S, Park M, et al. Development of a Laboratory-safe and Low-cost Detection
- 446 Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19). Exp Neurobiol.
- 447 2020;29(2):107-119. doi:10.5607/en20009
- 448 14. Yang T, Wang YC, Shen CF, Cheng CM. Point-of-Care RNA-Based Diagnostic Device for
- 449 COVID-19. Diagnostics. 2020 Mar 18;10(3). PubMed PMID: 32197339.
- 450 15. Khandker SS, Nik Hashim NHH, Deris ZZ, Shueb RH, Islam MA. Diagnostic Accuracy of
- Rapid Antigen Test Kits for Detecting SARS-CoV-2: A Systematic Review and Meta-
- 452 Analysis of 17,171 Suspected COVID-19 Patients. J. Clin. Med. 2021; 10(16):3493.
- 453 https://doi.org/10.3390/jcm10163493
- 16. Ethiopian public health institute, EPHI. Interim Guide for SARS CoV- 2 Antigen Rapid
- Diagnostic Testing in Ethiopia. EPHI, February 2022, Addis Ababa, Ethiopia

- 456 17. Sisay A, Abera A, Dufera B, Endrias T, Tasew G, Tesfaye A, et al,. Diagnostic accuracy of 457 three commercially available one step RT-PCR assays for the detection of SARS-CoV-2 458 in resource limited settings. *PLoS One*. 2022 Jan 20;17(1):e0262178. doi: 459 10.1371/journal.pone.0262178. PMID: 35051204; PMCID: PMC8775315
- 18. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl).

  2020;133(9):1032-1038. doi:10.1097/CM9.000000000000775.
- 19. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9(1):386-389. Published 2020 Feb 17. doi:10.1080/22221751.2020.1729071.

467

468

469

470

471

472

473

474

475

476

477

478

479

480

- 20. Wang L, Shi Y, Xiao T, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition). Ann Transl Med. 2020;8(3):47. doi:10.21037/atm.2020.02.20
  - 21. Ngo Nsoga MT, Kronig I, Perez Rodriguez FJ, Sattonnet-Roche P, Da Silva D, Helbling J, et al. (2021) Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2. PLoS ONE 16(6): e0253321. https://doi.org/10.1371/journal.pone.0253321
  - 22. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. *EBioMedicine*. 2021; 69:103455. doi:10.1016/j.ebiom.2021.103455
  - 23. Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021; 27(3):472.e7-472.e10. doi:10.1016/j.cmi.2020.11.004
- 24. Thirion-Romero I, Guerrero-Zúñiga DS, Arias-Mendoza DA, et al. Evaluation of Panbio rapid antigen test for SARS-CoV-2 in symptomatic patients and their contacts: a multicenter study. *Int J Infect Dis.* 2021; 113:218-224. doi:10.1016/j.ijid.2021.10.027
- 25. Central Statistics Agency. Summary and Statistical Report of the 2007 Population and Housing Census Results. Central Statistical Agency, Addis Ababa Ethiopia. 2008. accessed March 12, 2022.

- 26. World Health Organization (WHO). COVID-19 Preparedness Bulletin Ethiopia.
- https://extranet.who.int/sph/news/covid-19-preparedness-bulletin-ethiopia. Accessed
- 487 date March 12, 2022.
- 488 27. WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected human
- 489 cases: interim guidance; 2020. Available from:
- 490 https://apps.who.int/iris/handle/10665/331501?locale-attribute
- 491 =en&fbclid=IwAR1XbKVPhGao
- oWRr7F8LArwK9YDngyK2fhCGILll5xfVs9u89S3olue5gc. Accessed date March 12,
- 493 2022.
- 494 28. World Health Organization (WHO). COVID-19 Ag Rapid Test Device (Nasopharyngeal).
- 495 IFU for Panbio EUL 0564-032-00.https://www.who.int/publications/m/item/EUL-0564-
- 496 032-00. Accessed date March 12, 2022.
- 497 29. Manufacturer's Instructions for Use (IFU), <a href="https://dam.abbott.com/en-">https://dam.abbott.com/en-</a>
- 498 gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-AsymptomaticSe.pdf. Accessed
- 499 date March 12, 2022.
- 30. Manufacturer's Instructions for Use (IFU), Real-time fluorescent RT-PCR kit for
- detecting 2019-nCoV, MFG030010. BGI Biotechnology (Wuhan) Co., Ltd, Building B2,
- Zone B/C/D, Wuhan National Bioindustry Base, NO.666 Gaoxin Avenue, East Lake High-
- tech Development Zone, Wuhan
- 504 31. Cohen's kappa Kappa value interpretation (see Landis, JR & Koch, GG (1977). The
- measurement of observer agreement for categorical data. Biometrics, 33, 159-174).
- 32. Just another Gibbs Sampler. <a href="https://mcmc-jags.sourceforge.io/">https://mcmc-jags.sourceforge.io/</a>.
- 507 33. Denwood Matthew J. (2016). runjags: An R Package Providing Interface Utilities,
- 508 Model Templates, Parallel Computing Methods and Additional Distributions for MCMC
- 509 Models in JAGS. Journal of Statistical Software, 71(9), 1–25. doi: 10.18637/jss.vo71.io9).
- 34. R Core Team (2022). R: A language and environment for statistical computing. R
- Foundation for Statistical Computing, Vienna, Austria. URL <a href="https://www.R-">https://www.R-</a>
- 512 <u>project.org/.</u>
- 35. Andri Signorell et mult. al. (2021). DescTools: Tools for descriptive statistics. R
- package version 0.99.44.

36. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al.. Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19. *J Clin Microbiol*. 2020. Nov 2; JCM.02589-20. [PMC free article] [PubMed] [Google Scholar]

519

520

521

522

523

524

525

526

527

528

529

530

534

535

539

540

541

- 37. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al.. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. *Journal of Clinical Virology*. 2020. Oct 16; 104659. doi: 10.1016/j.jcv.2020.10465
- 38. Akingba OL, Sprong K, Marais G, Hardie DR. Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South Africa. *Journal of Clinical Virology Plus*. 2021;1(1):100013. doi:10.1016/j.jcvp.2021.100013
  - 39. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al., Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. J Infect. 2021 Mar;82(3):391-398. doi: 10.1016/j.jinf.2021.02.014. Epub 2021 Feb 13. PMID: 33592253; PMCID: PMC7881288.
- 40. World Health Organization. COVID-19 Strategy Update. 14 April 2020 (https://www.who.int/publications/i/item/covid-19-strategy-update---14-april-2020, accessed March 12, 2022.
  - 41. FIND. Rapid diagnostic tests for COVID-19 (https://www.finddx.org/wpcontent/uploads/2020/05/FIND COVID-19 RDTs 18.05.2020.pdf, accessed 12 March 2022).
- 42. Africa CDC. New guidance to expand rapid antigen testing for COVID-19 response in
  Africa released.https://africacdc.org/download/interim-guidance-on-the-use-of-rapidantigen-tests-for-covid-19-response/. Accessed date March 12, 2022.
  - 43. Krüger LJ, Gaeddert M, Tobian F, et al. The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2-Evaluation of the accuracy and ease-of-use. *PLoS One.* 2021;16(5):e0247918. Published 2021 May 27. doi:10.1371/journal.pone.0247918

- 44. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio<sup>™</sup> COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. *Clin Microbiol Infect*. 2021; 27(4):636.e1-636.e4. doi:10.1016/j.cmi.2020.12.022
- 45. Altamimi, AM, Obeid, DA, Alaifan, TA, et al. Assessment of 12 qualitative RT-PCR commercial kits for the detection of SARS-CoV-2. *J Med Virol.* 2021; 93: 3219-3226. https://doi.org/10.1002/jmv.26900
- Supplementary materials, S1-S6 (supplementary files, S1-S6)..
- 552 S1: BLCM. Code. R

544

545

546

547

548

549

550

562

563

564

565

- 553 S2: performance analysis with weakly informative priors
- 554 S3: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot)
- for sensitivity of Panbio rapid antigen test
- 556 S4: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot)
- 557 for sensitivity of RT-PCR
- 558 S5: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot)
- for specificity of Panbio rapid antigen test
- 560 S6: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot)
- 561 for specificity of RT-PCR

Annex 1- Stratification of the samples in the four selected sites we allocate the total proposed 438 sample in to the four selected sites accordingly.

Health Facility name	Assigned code	Assigned sample size
Zewditu memorial Hospital	01	46
Ras Desta Damtew memorial	02	230
Hospital		
Kazanchis Health Ceneter	03	116
Kotebe Health Center	04	46